Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide

American Journal of Hematology

Volumn 73, Issue 1, 2003, Pages 48-53

  Lee, Fa Chyi ^a,b   Merchant, Shakil H ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Interleukin 6; Multicentric Castleman's disease; Thalidomide

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; INTERLEUKIN 6; STEROID; THALIDOMIDE; TROPONIN I;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AXILLARY LYMPH NODE; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LYMPH NODE BIOPSY; PRIORITY JOURNAL;

ADULT; ANEMIA; ANTIBODIES, VIRAL; AXILLA; BIOPSY; CYTOKINES; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LEUKOCYTE COUNT; LYMPH NODES; LYMPHATIC DISEASES; PLEURAL EFFUSION; THALIDOMIDE; THROMBOCYTOPENIA; TOMOGRAPHY, X-RAY COMPUTED; TROPONIN I;

EID: 0037405320     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10310     Document Type: Article

References (37)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-830.
2. Peterson B, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993;20:636-647.
3. Cesarman E, Knowles D. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol 1999;9:165-174.
4. Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma and multicentric Castleman's disease. Virology 2000;269:335-344.
5. Brousset P, Cesarman E, Meggetto F, et al. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease. Hum Pathol 2001;32:95-100.
6. O'Larry J, Kennedy M, Howells D, et al. Cellular localization of HHV-8 in Castleman's disease: is there a link with lymph node vascularity? J Clin Pathol: Mol Pathol 2000;53:69-76.
7. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 1997;175:1198-1201.
8. Boulanger E. Human herpesvirus 8 (HHV8).II. Pathologenic role and sensitivity to antiviral drugs. Ann Biol Clin 1999;57:19-28.
9. Lanzafame M, Carretta G, Trevenzoli M, et al. Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Infect 2000;40:90-91.
10. Greiner T, Armitage J, Gross T. Atypical lymphoproliferative disease. Hematology 2000:133-146 (Education Program of ASH 2000).
11. Ishiyama T, Nakamura S. Akimoto Y, et al. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease. Br J Haematol 1994:86:483-489.
12. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman's disease in HIV-infected patients. Blood 2000;96:2069-2073.
13. Aoki Y, Yarchoan R, Wyvill K, et al. Detection of viral interleukin-6 in Kaposi's sarcoma-associated herpesvirus-linked disorders. Blood 2001;97:2173-2176.
14. Hastings RC, Trautman JR, Enna CD, et al. Thalidomide in the treatment of erythema nodosum leprosum. Clin Pharmacol Ther 1970;11: 481-487.
15. Clark T, Edom N, Larson J, et al. Thalidomide capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001;24:87-117.
16. Rajkumar V. Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol 2001;19:3593-3595.
17. Urbanska-Rys H, Wiersbowska A, Stepien H, et al. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6), interleukin-11 (IL-11), oncostatin M (OSM) and soluble interleukin-6 (IL-6) receptor (slL-6) inpatients with multiple myeloma. Eur Cytokine Netw 2000;11:443-451.
18. Rowland TL, McHugh SM, Deighton J, et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998;40: 11-20.
19. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease. Cancer 1999;85:706-717.
20. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman's disease. Cancer 2001;92:670-676.
21. See A, Cerf M, Rigarud D, et al. Treatment of an abdominal form of Castleman's disease by chemotherapy. Ann Gastroenterol Hepatol (Paris) 1986:22:19-22.
22. Chan TM, Cheng IK, Wong KI, et al. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). Nephron 1993:65:628-632.
23. Pavlidis NA, Skopouli FN, Bai MC, et al. A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease). Med Pediatr Oncol 1990;18:333-335.
24. Bordeleau L, Bredeson C, Markman S. 2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol 1995;91: 668-670.
25. Rieu P, Droz D, Gessain A, et al. Retinoic acid for treatment of multicentric Castleman's disease. Lancet 1999;354:1262-1263.
26. Andres E, Maloisel F. Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 2000;11:1613-1614.
27. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferonalpha, Clin Infect Dis 2000;31:602-604.
28. Barbounis V, Efremidis A. A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Anticancer Res 1996;16:545-547.
29. Hisatake J, Ishiyama T, Akimoto Y, et al. Autoimmune hemolytic anemia associated with multicentric Castleman's disease with a 28-year history. Rinsho Ketsueki 1994;35:768-773.
30. Repetto L, Jaiprakash MP, Selby PJ, et al. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplant. Hematol Oncol 1986;4:213-217.
31. Nishmoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
32. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi's sarcoma-associated herpesvirus-related multicentric Castleman's disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-3475.
33. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74: 1360-1367.
34. Beck JT, Hsu SM, Wijdenes J, Bataille R, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. New Engl J Med 1994;330(9):602-605.
35. Nicolosi AC, Almassi GH, Komorowski R. Cardiac tamponade secondary to giant lymph node hyperplasia (Castleman's disease). Chest 1994;105:637-639.
36. Nijsten MWN, de Groot ER, ten Duis HJ, Klasen HJ, Hack CE, Aarden LA. Serum levels of interleukin-6 and acute phase responses. Lancet 1987;2:921.
37. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-1216.